

Sister Study Breast Cancer Events (any type) ¹ Stratified by Race/Ethnicity ²: Data Release 8.1 ³

Characteristic	Non-Hispanic White		Black (includes Hispanic Black)		Non-Black Hispanic/Other	
	N (total = 3,257)	%	N (total = 304)	%	N (total = 242)	%
Breast Cancer Subtype for 1st Diagnosis						
Invasive ⁴	2,456	75.4	218	71.7	188	77.7
Ductal only (no lobular component) ⁵	1,736	53.3	142	46.7	128	52.9
Lobular only (no ductal component) ⁵	231	7.1	8	2.6	12	5.0
Ductal and lobular ^{5,6}	166	5.1	8	2.6	11	4.5
Inflammatory	5	0.2	1	0.3	0	0.0
Paget's	8	0.2	2	0.7	0	0.0
Phyllodes ⁷	5	0.2	0	0.0	0	0.0
Other/unknown if ductal or lobular ⁸	305	9.4	57	18.8	37	15.3
<i>In situ</i>	773	23.7	83	27.3	52	21.5
Ductal only (no lobular component) ⁹	640	19.6	74	24.3	44	18.2
Lobular only (no ductal component) ⁹	104	3.2	6	2.0	8	3.3
Ductal and lobular ^{6,9}	17	0.5	0	0.0	0	0.0
Paget's	5	0.2	0	0.0	0	0.0
Other/unknown if ductal or lobular ¹⁰	7	0.2	3	1.0	0	0.0
Invasiveness unknown ¹¹	28	0.9	3	1.0	2	0.8
Stage at 1st Breast Cancer Diagnosis ¹²						
0	705	24.2	66	27.7	46	23.1
I	1,484	50.9	103	43.3	98	49.2
II	567	19.4	54	22.7	38	19.1
III	141	4.8	14	5.9	16	8.0
IV	19	0.7	1	0.4	1	0.5
<i>Unknown, missing, cannot stage</i>	341		66		43	
Estrogen Receptor (ER) Status for 1st Breast Cancer Diagnosis ¹²						
Positive	2,357	85.3	172	76.8	150	82.4
Negative	403	14.6	50	22.3	32	17.6
Borderline	3	0.1	2	0.9	0	0.0
<i>Unknown, missing, not performed</i>	494		80		60	
Progesterone Receptor (PR) Status for 1st Breast Cancer Diagnosis ¹²						
Positive	1,953	73.1	129	60.3	121	67.6
Negative	711	26.6	84	39.3	58	32.4
Borderline	6	0.2	1	0.5	0	0.0
<i>Unknown, missing, not performed</i>	587		90		63	
HER2 Amplification Status for 1st Breast Cancer Diagnosis ¹²						
Positive	288	12.6	27	15.9	27	17.0
Negative	1,964	85.9	142	83.5	131	82.4
Borderline	35	1.5	1	0.6	1	0.6
<i>Unknown, missing, not performed</i>	970		134		83	

Characteristic	Non-Hispanic White		Black (includes Hispanic Black)		Non-Black Hispanic/Other	
	N (total = 3,257)	%	N (total = 304)	%	N (total = 242)	%
Combined ER, PR, HER2 Status ¹²						
Triple negative (ER-, Pr-, and HER2-)	215	8.0	35	16.0	18	10.2
Not triple negative	2,463	92.0	184	84.0	158	89.8
<i>Unknown, missing, not performed</i>	579		85		66	
Diagnosis Confirmation ¹³						
Medical	2,671	82.0	209	68.8	182	75.2
NDI Plus or death certificate	27	0.8	11	3.6	1	0.4
None	559	17.2	84	27.6	59	24.4
Age (in years) at Breast Cancer Diagnosis ¹⁴						
Under 50	332	10.2	48	15.8	35	14.5
50-64	1,514	46.5	148	48.7	136	56.2
65 and older	1,411	43.3	108	35.5	71	29.3
Menopausal Status at 1st DCIS or Invasive Breast Cancer						
Pre-menopausal	528	16.3	59	19.5	54	22.3
Post-menopausal	2,714	83.7	244	80.5	188	77.7
<i>Unknown</i>	15		1		0	

Abbreviations: BrCa= Breast cancer; DCIS=Ductal carcinoma *in situ* ; LCIS = Lobular carcinoma *in situ* ; MR = Medical report (medical record and/or pathology report)

¹ Breast cancer events (any type) are defined by the following ICD10 codes: D05 (includes lobular carcinoma *in situ*, ductal carcinoma *in situ*, other and unspecified *in situ* breast carcinomas), C50 (all invasive breast cancer), and D48.6 (neoplasm of uncertain behavior of breast)

² Excludes n=1 where race/ethnicity is missing

³ Data release 8.1 includes events from follow-up phases that closed **on or before 9/23/2018**, excluding all data from participants who have withdrawn their data from the study (n=3). To be considered a breast cancer event, breast must be the primary site, and the cancer diagnosis must have occurred after the participant's baseline date. Consequently, Data Release 8.1 breast cancer events (any type) exclude a) through c) below:

- a) Breast cancers diagnosed prior to participant's baseline date;
- b) Breast cancers diagnosed with unknown timing relative to baseline;
- c) Unknown primary cancer diagnoses where breast was unlikely to be the primary site, but the possibility could not be ruled out

⁴ Includes 'presumed invasive' (i.e. a carcinoma *in situ* with positive nodes)

⁵ Ductal only, Lobular only, and Ductal and Lobular exclude inflammatory breast cancer and Paget's

⁶ Includes BrCa events with a) tumors with mixed ductal and lobular characteristics and/or b) multiple tumors of different histology (e.g. a ductal only tumor and a lobular only tumor)

⁷ Phyllodes is neither ductal nor lobular; it is a sarcoma

⁸ Includes: a) Invasive but unknown if ductal or lobular, these are typically self-report without MR confirmation; b) Invasive type "neither ductal nor lobular, not otherwise specified", these are typically self-report without MR confirmation; and c) Per MR, presumed invasive - *in situ* tumor, positive nodes;

⁹ *In situ* Ductal only, *in situ* Lobular only, and *in situ* Ductal and Lobular exclude *in situ* Paget's

¹⁰ Includes: a) *In situ* but unknown if ductal or lobular; b) *In situ* type "neither ductal nor lobular, not otherwise specified"

¹¹ Invasiveness unknown includes: a) Unknown if invasive or *in situ* and unknown if ductal or lobular; b) Ductal but unknown if invasive or *in situ* ; c) Lobular but unknown if invasive or *in situ* ; d) Neither ductal nor lobular (other) but not otherwise specified and unknown if invasive or *in situ* ; e) Per MR, unable to determine if DCIS or atypical ductal hyperplasia; and f) Per MR, unable to determine if LCIS or atypical lobular hyperplasia ¹² Priority for stage and ER/PR/HER2 status when diagnosis is reported by multiple sources: Medical record>Breast Cancer Follow-Up Form

¹³ Medical confirmation of reported breast cancer is generally from medical records but may only include pathology report; National Death Index (NDI) Plus or death certificate confirmation is specific to cases that do not have medical confirmation

¹⁴ For those missing age at diagnosis, age was imputed as the midpoint of the range of plausible ages at diagnosis